Application of compound in preparation of drugs for treatment of renal cell carcinoma

A kidney cancer and drug technology, applied in the field of medicine, can solve the problems of large side effects and low efficiency

Active Publication Date: 2020-01-03
JIANGSU KANION PHARMA CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The occurrence of renal cancer is the result of the joint action of genetic factors and environmental factors. Renal cancer cells are highly resistant to radiotherapy and chemotherapy, while traditional immunotherapy represe...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of compound in preparation of drugs for treatment of renal cell carcinoma
  • Application of compound in preparation of drugs for treatment of renal cell carcinoma
  • Application of compound in preparation of drugs for treatment of renal cell carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 Effects of 1,2,3,4,6-pentagalloylglucose on renal cancer cells and prostate cancer 1. Experimental materials

[0021] 1.1 Drugs and reagents: 1,2,3,4,6-pentagalloylglucose (MCE); RPMI1640 (GIBCO), fetal bovine serum (GIBCO); MTT (sigma).

[0022] 1.2 Cells: Renca (CRL-2947, purchased from ATCC); RM-1 cell line (Shanghai Yansheng Industrial Co., Ltd.).

[0023] 1.3 Instruments and equipment: electronic balance (Sartorius); centrifuge (Anhui Zhongjia); Flex station 3 calcium flow workstation (MD); inverted microscope (OLYPUS).

[0024] 2. Experimental method

[0025] 2.1 Cell culture

[0026] Cells were subcultured and inoculated in culture flasks at 37°C, 5% CO 2 , cultured in an incubator with saturated humidity, when the cells in the culture flask are basically overgrown (the cells remain in the logarithmic growth phase), discard the culture medium, add an appropriate amount of PBS solution to gently shake, discard, and then add 0.25% Digest 1ml of trypsi...

experiment example 21

[0036] Experimental example 2 Effect of 1,2,3,4,6-pentagalloyl glucose on the binding of PD-1 / PD-L1 in vitro

[0037] 1. Experimental materials

[0038] 1.1 Drugs and reagents: 1,2,3,4,6-pentagalloylglucose (MCE); RPMI1640 (GIBCO), fetal bovine serum (GIBCO); PD1 / PD-L1 Binding Assay Kits (cisbio).

[0039] 1.2 Instruments and equipment: electronic balance (Sartorius); microplate reader (PE).

[0040] 2. Experimental method

[0041] Dissolve the drug in DMSO to 50mM as the storage solution, dilute it to 30uM / mL with the diluent in the kit before the experiment, and then use this as the high concentration, and then dilute it to 30, 10, 3.33, 1.11, 0.37uM / mL according to the three-fold dilution. There are 5 concentrations in mL. Add 2uL diluted compounds of different concentrations, 4uL Tag1-PD-L1 protein, and 4uL Tag2-PD1 protein according to the order of the kit operation instructions. After standing for 15 minutes at room temperature in the dark, add 10uL pre- The mixed ant...

experiment example 31

[0044] Experimental Example 3 Inhibitory Effect of 1,2,3,4,6-Pentagalloyl Glucose on Transplanted Tumors in Nude Mice

[0045] 1. Experimental materials

[0046] 1.1 Drugs and reagents

[0047] 1,2,3,4,6-pentagalloylglucose (MCE); RPMI1640 (GIBCO), fetal bovine serum (GIBCO); PD1 / PD-L1 Binding Assay Kits (cisbio).

[0048] 1.2 Animals and Cells

[0049] Renca (CRL-2947, purchased from ATCC); RM-1 cell line (Shanghai Yansheng Industrial Co., Ltd.); nude mice (Center for Comparative Medicine, Yangzhou University, SCXK (Su) 2017-0007).

[0050] 1.3 Instruments

[0051] Syringe (1mL, needle size 27); sterile surgical instruments (including scalpels, scissors, tweezers, needle holders, etc.)

[0052] 2. Experimental method

[0053] 2.1 Cell culture

[0054] Tumor cells were subcultured and inoculated into culture flasks at 37°C, 5% CO 2 , cultured in an incubator with saturated humidity, when the cells in the culture flask are basically overgrown (the cells remain in the log...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of 1,2,3,4,6-pentagalloylglucose, or an optical isomer, or a racemate, or a solvate, or a pharmaceutically acceptable salt in the preparation of drugs for the treatment or prevention of renal cancer or prostate cancer. According to the application, an experiment shows that the 1,2,3,4,6-pentagalloylglucose can significantly reduce the cell activity of Renca renal cancer and RM-1 prostate cancer in vitro, can reduce the tumor weight of tumor bearing mice in vivo, and it is proved that the 1,2,3,4,6-pentagalloylglucose has an inhibitory effect on two kinds oftumors, and PD-L1 gene expression is detected in two kinds of tumor bearing mice, so that it can be preliminarily inferred that the 1,2,3,4,6-pentagalloylglucose may play an anti-tumor role mainly byblocking PD1/PD-L1.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of a compound in the preparation of a drug for treating renal cell carcinoma. Background technique [0002] Renal cancer is the most common malignant tumor of the urinary system in my country, and it is listed among the top ten malignant tumors in Western countries. The occurrence of renal cancer is the result of the joint action of genetic factors and environmental factors. Renal cancer cells are highly resistant to radiotherapy and chemotherapy, while traditional immunotherapy represented by interleukin and interferon has a very low efficiency in the treatment of renal cancer. The side effects are large, making the prevention and treatment of renal cancer an important and difficult point in the field of tumor research. Abnormalities of cellular immunity and humoral immunity exist in patients with RCC, including CD4+T cell damage, CD8+T lymphocyte and regulator...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7024A61P35/00
CPCA61K31/7024A61P35/00
Inventor 肖伟王红梅李良周军刘莉娜朱方方顾莎莎王振中
Owner JIANGSU KANION PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap